Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11513546 | 0.93 | BCHE (0.60) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL11513551 | 0.93 | BCHE (0.60) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL5177047 | 0.93 | CTSS (0.56) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL14433709 | 0.93 | CTSS (0.58) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL1122463 | 0.93 | CTSS (0.58) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL13884485 | 0.93 | CTSS (0.58) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL22034518 | 0.88 | CTSS (0.58) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL22034521 | 0.88 | CTSS (0.58) | CTSSCTSLFOLH1CTSBCTSK | |
| SCHEMBL9068032 | 0.86 | CTSS (0.57) | CTSSCTSLCTSBCTSKCASP1 | |
| SCHEMBL18758793 | 0.85 | CTSS (0.55) | CTSSCTSLFOLH1CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063540-A | Solid-phase polypeptide synthesis method based on aqueous phase | 国科大杭州高等研究院 | 2024-05-24 | — | — | CN | disclosed |
| US-20020132776-A1 | Inhibitors of transglutaminase | N-ZYME BIOTECH GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002036798-A2 | INHIBITORS OF TRANSGLUTAMINASES | N-ZYME BIOTEC GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | TGM2, GNMT, TGM1 | CTSS 1533/4885CTSL 1518/4885FOLH1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.